CONTENTS:
1. Imidazopyridines: A New Family of Hypnoselective and Anxioselective Drugs
2. Diversity of GABA[subscript A]-Omega Receptor Complexes
3. Identification in the Brain and Pharmacological Properties of GABA[subscript A] Receptors Associated with Different [alpha]-Subunits
4. Drug-Receptor Interactions in Anxiety
5. Neurosteroids: Relevance to the Mechanism of Action of Anxiolytic Drugs
6. Cellular Role and Pharmacological Implications of Mitochondrial P-Sites Recognizing Diazepam Binding Inhibitor (DBI) as a Putative Endogenous Ligand
7. Alpidem: Synthesis, Physicochemical Properties and Structure-Activity Relationships
8. The Mechanism of Action of Alpidem
9. The Psychopharmacological Profile of Alpidem
10. Tolerance and Dependence Studies with Alpidem
11. Mechanisms Involved in the Development of Rapid Tolerance to and Dependence on Benzodiazepines
12. Distribution and Metabolism of Alpidem in Several Animal Species and Humans
13. Pharmacokinetic Profile of Alpidem: Effect of Age and Pathological Conditions
14. Anxiolytics and Electrogenesis: Alpidem Effects on Waking EEG and Sleep Architecture
15. Comparison of Alpidem, Lorazepam and Placebo Effects in a Combined Clinical/Psychometric Study: A New Approach for Assessing the Behavioral Costs and Benefits of Anxiolytic Drug Therapy
16. Double-Blind Randomized Studies on the Therapeutic Action of Alpidem in Generalized Anxiety Disorders: A Review 155 17. Efficacy of Alpidem in Anxiety Disorders: A Review of Four Placebo-Controlled Studies
18. Life Stress Event Models as a Predictor of Antianxiety Action: A Review of Five Controlled Studies
19. A Comparative Study of Alpidem Versus Buspirone
20. Safety and Efficacy of Alpidem: Long-term Open-Label Observations
21. Safety Profile of Alpidem
22. Anxiolytic Therapy in the Elderly: Experiences with Alpidem
23. Withdrawal Symptoms and Rebound with Anxiolytic Drugs: Experiences with Alpidem
24. Withdrawal Symptoms Following Anxiolytic Discontinuation
Concluding Remarks
